1www.demicco.ch

Executive SummaryCompany: BMDSys Optical GmbH

Copy: No. 1/3

Date: October, 2014

Business plan: 3 business years plan

Founder (team): Volker Schall (CEO)Dr. rer. nat. Gertrud Lembke (CTO)

Any information in this summary is confidential! Reproduction and copy ing requires the agreement of De Micco & Friends Group!

2www.demicco.ch

The contents of this document are strictly confidential and were obtained inter alia frompublicly available information. This document (the “Concept, Structure & InvestorsPresentation”) is a marketing document and not a regulatory document.

The sole purpose of this document is to assist the recipient in deciding whether to proceed witha further investigation of an investment in BMDSys Optical GmbH, registered in Germany,(“the “COMPANY”) and the "Proposed Transaction". This document does not purport to be all‐inclusive or to contain all the information that a prospective interested party may desire toevaluate the Proposed Transaction. This document has been prepared only for informationalpurposes relating to the Proposed Transaction only.

Neither COMPANY nor its affiliates or representatives assumes any responsibility for theindependent verification of any of the information set forth in this document, or of anyadditional evaluation material made available in connection with any further investigation ofthe Proposed Transaction. Neither COMPANY nor its affiliates or representatives make anyexpress or implied representation or warranty as to the accuracy or completeness of theinformation contained in, or for any omissions from, this document or any additional evaluationmaterial made available in connection with any further investigation of the ProposedTransaction. In addition, COMPANY (on its own behalf and on behalf of its affiliates orrepresentatives) expressly disclaims any and all liability which may be based on suchinformation, errors therein or omissions there from.

Neither the receipt of this document by any person nor any information contained herein orsupplied herewith or subsequently communicated to any person in connection with theProposed Transaction is or is to be taken as constituting the giving of investment advice to anysuch person. It is the responsibility of the recipient, before entering into any transaction, tomake its own appraisal of the Proposed Transaction, its advantages and risks, without relyingexclusively on the information that was provided to the recipient. If it deems necessary oruseful, the recipient may consult its own legal, tax, financial, accounting and other professionaladvisors.

In furnishing this document, neither COMPANY nor its affiliates or representatives undertakesany obligation to provide the recipient with access to any additional evaluation material.COMPANY reserves the right to negotiate with one or more parties at any time and to enter intoa definitive agreement, without prior notice to the recipient or any other party. COMPANYreserves the right to terminate, at any time, solicitation of indications of interest in theProposed Transaction or in the further participation in the investigation and proposal process byany party.

Finally, COMPANY reserves the right to modify, at any time, any procedures relating to thisprocess without assigning any reason therefore. The information contained herein or madeavailable in connection with any further investigation of the Proposed Transaction is strictlyconfidential. This document may not be photocopied, reproduced or distributed to any thirdparty at any time without the prior written consent of COMPANY. All communications, inquiriesand requests for information relating to these materials should be addressed to COMPANY.

COMPANY is the primary contact for the Proposed Transaction. Please direct all inquiriesregarding the Proposed Transaction to the representatives of COMPANY referred to below.Interested parties will be required to sign a Non Disclosure Agreement (NDA) and send it, byemail and by post/hand, to the address below.

De Micco & Friends Group Corporation

(advisors, lawyers, auditors)Switzerland

and 

BMDSys Optical GmbHGermany

DISCLAIMER

3www.demicco.ch

Contents

Overview

1. Executive summary

2. Product

3. Founder and management team

4. Market

5. Chances and risks

6. Financial planning

7. Offer for investors

Overview

1. Executive summary

2. Product

3. Founder and management team

4. Market

5. Chances and risks

6. Financial planning

7. Offer for investors

4www.demicco.ch

Overview

5www.demicco.ch

OverviewProject data

Entrepreneurs: Volker Schall and Dr. rer. nat. Gertrud Lembke 

Planning: Continuation, development and marketing of an already developed technology 

Business location: Kurfürst‐Schönborn‐Straße 25, 56070 Koblenz, Germany

Legal form: GmbH (German Limited)

Company name: BMDSys Optical GmbH 

Start of  operation : previous company BMDSys GmbH 2005

Funding: Own funding and private equity

Future prospects: A unique product for risk stratification of sudden cardiac death (SCD) has been developed that now has to be introduced worldwide. 

6www.demicco.ch

1.Executive Summary

7www.demicco.ch

1. Executive SummaryProduct/Business model

In the industrialized countries heart diseases are cause of death number one!

Worldwide approx. 9 mio. people die per year because of sudden cardiac death (SCD). In Germany there are 100,000 cases per year.

In approximately 80 % of all cases high frequent heart arrhythmias are responsible. In principle every person can be in danger.

Sudden cardiac death (SCD) is in approx. 50 % of all cases the first manifestation of a heart disease. The affected persons did not know about their heart problem and thus could not take any preventive action.

The BMDSys Optical GmbH offers with a unique technical innovation a solution for this problem!

8www.demicco.ch

1. Executive SummaryProduct/Business model

The diagnostic system developed by BMDSys Optical GmbH allows a cardiologist to estimate the risk for sudden cardiac death within five minutes based on the heart‘s magnetic signals.

The team of BMDSys Optical GmbH and the physicians accompanying the clinical studies developed a technology that allows an individual risk stratification, which saves many lives.

Thus, this innovation is not only a highly interesting investment, but of high medical, clinical, sociological and economical relevance.

Investors can participate actively in the company and profit from the future prospects.

9www.demicco.ch

2.Product/Service

10www.demicco.ch

2. Product2.1 Previous model

BMDSys Optical GmbH with its team is the follow-up of BMDSys Production GmbH, which developed, produced and sold with the same staff the first systems for MFI diagnostics.

With its research and development activities it achieved breaking results and international acknowledgement. For the first time a reliable system was available that could detect an enhanced risk for sudden cardiac death.

Approx. 8 M. EURO were invested in the industrialization of the first version.

11www.demicco.ch

2. Product2.1 Previous model

The systems of the first generation work perfectly and have successfully been used in various hospitals.

However, the used technology requires liquid helium cooling, which means an expense of approx. 700 to 900 K EURO during a mean life cycle of 10 years. This generates high costs and reduces the economical effectiveness of the systems in the clinical use.

This lack of economical efficiency of the previous model has reduced the chances in sales in such a way that the former company could not reach sustainable profit.

12www.demicco.ch

2. Product2.2 APOLLO CXS – the new sensor generation

Test finished

Prototype ready

More efficient

Low maintenance costs

ISO certification

Ready for market

Cheaper 

New technology

Quicker production

Without cooling

Use in hospitals

Direct sales

Distributors

Sports organisations

Orders are placed!

Potential health insurances

High margins (50‐60 %)

First mover Technology

International demand

Mass production

Das team of BMDSys Optical GmbH developed, based on the original technology, a new system that makes the helium cooling superfluous. In this way the operating costs are importantly reduced.

Thus, the new systems are highly interesting for any hospital worldwide that offers heart diagnostics. The prototype developed under the label APOLLO CXS is already available. All tests have been successful.

13www.demicco.ch

2. Product2.3 Projected development schedule

Development processes Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Phase 6

Development of the first system (helium)

Tests in hospitals and universities

First marketing national

Development APOLLO CXS (OPM)

Test APOLLO CXS

Start series production and marketing

Mass production, worldwide sales

Sales , marketing Development phases

International marketing

To distribute the APOLLO CXS with the new optical technology (OPM) in clinics and medical centers, a series production has to be set up and financed. For the international market introduction a period of 1-2 years is scheduled. Already 8-12 months after project start, revenues are possible. The production time per system will be reduced in medium term to 4 weeks for being able to respond to the increasing demand. In 2 years an industrial mass production will become necessary.

today mass production

14www.demicco.ch

2. Product2.3 Projected development schedule

Parallel to the development of the series production, direct and indirect sales channels will be set up to acquire new customers and advanced bookings.

For systems based on the new technology, orders from the Chinese distributor are already included in the distribution contract with the previous company BMDSys Production GmbH.

The marketing for the new technology has not been started yet.

15www.demicco.ch

2. Product2.3 Projected development schedule

APOLLO CXS delivers information about the actual electrophysiological status of the heart based on the record of the heart‘s magnetic signals.

The new system can become a standard diagnostic tool and can be easily combined with other diagnostics.

APOLLO CXS provides in the handling of heart patients in the clinical routine a new parameter that surely in the future will be considered for inclusion in the guidelines of cardiology.

APOLLO CXS leads to a paradigm change in cardiac diagnostics!

16www.demicco.ch

2. Product2.3 Projected development schedule

ADVANTAGES:

Quick and easy: An MFI examination takes maximum 5 minutes including data analysis. No patient preparation is necessary, not even undressing.

Non-invasive: The sensor system is positioned over the patient‘s chest, it does not touch the patient!

Side-effect-free: The data acquisition is pure passive, no contrast agents are necessary and no ionizing radiation is used.

Cost efficient: No helium cooling, room temperature leads to minimum operational costs.

Repeatable: The examination can be repeated as often as required as there are no side effects. The diagnosis is applicable for all patient groups.

17www.demicco.ch

2. Product2.4 Production/production costs, sales prices

Current production costs per system based on the new technology:

348,000 EURO

Production costs considering a rationalized series production (from 2nd year)

290,000 EURO

Sales prices:

Price per system for direct sales

650,000 EURO

Price per system for sales via distributors:

500,000 EURO

18www.demicco.ch

2. Product2.5 Technology

The technology have two key fields: 

The management of the environmental noise, obtained with a intelligent distribution of the load to the different system component (Shielding, sensor, real‐time signal processing, software noise compensation)

The Analysis algorithm to extract the clinical relevant information from the magnetic data.

More information will be given by Dr. Erné

19www.demicco.ch

3.Management team

20www.demicco.ch

3. Management team3.1 Volker Schall, CEO

Volker Schall is a skilled banker and was able to successfully apply his knowledge in several production and sales companies in the sports industry.

Because of his expertise in the sports industry he knows the demands and problems in this field and thus can take advantage of the enormous potential of this market.

With his great experience as sales manager he is ideal for the scopes of marketing and sales of the optical diagnosis systems. Volker offers the whole necessary commercial and sales-related know-how for being able to lead BMDSys Optical GmbH towards a successful future.

21www.demicco.ch

3. Management team3.2 Dr. rer. nat. Gertrud Lembke, CTO

Since finishing her studies in physics and her doctorate in 2007, Dr. rer. nat. Gertrud Lembke (Ms.) was involved in the development of the optical magnetometers as a scientific employee at the University Hospital Jena.

Here, she extended her experience in the construction of a multichannel optical magnetic field sensor system as well as in simulation and construction of complex coil systems for well defined magnetic fields.

For her work on this system she received in 2010 the price „Young Investigator Award“ in the field „instrumentation“ at the international conference for biomagnetism BIOMAG 2010. She has the necessary physical know-how for optimizing the system for the use in clinical routine.

Gertrud is the technical developer from the start of the company.

22www.demicco.ch

3. Management team3.3 Further executive personnel and employees

Heike Kroker-Häge

Heike Kroker-Häge (Ms.) was responsible for the quality management of the superconducting MFI systems for a long time and knows the necessary steps for the registration of a medical product.

Furthermore, she has great experience as an executive assistant, in the scope of administration, national and international sales, export, import and purchase.

Dr. rer. nat. Reinhard Kürsten

Reinhard Kürsten studied physics in Hamburg and obtained his doctorate in 2002.

Subsequently, he was employed at the ‚Physikalisch-Technischen Bundesanstalt‘ in Berlin in the field of biomagnetic diagnostic. He was responsible for the final assembly and testing of the present MFI systems as well as for their installation.

His extensive knowledge regarding the behavior and treatment of highly permeable metal plates is of great importance for the future development.

23www.demicco.ch

3. Management team3.3 Further executive personnel and employees 

MsC. Yingbin Wu

Yingbin Wu works on the programming of the data acquisition and analysis software of the present MFI systems.

His knowledge and experience are of great importance for the adaption of the present programming to the optical magnetometers.

Furthermore, Yingbin Wu is responsible for the contact to a Chinese distributor who currently sells the helium cooled systems in China.

Dipl.-Ing. Klaus Brandt

As experienced development engineer in the field of medical engineering Mr. Brandt was involved in the whole production process of the helium cooled MFI systems since 2010.

In addition, as development and construction engineer, Klaus Brandt is responsible for the mechanical parts necessary for the operation of the system.

24www.demicco.ch

3. Management team3.4 Advisory board

Professor Dr. Sergio Nicola Erné

Has been involved since 1976 in research and development in all aspects of the technology of high sensitive magnetic measurement for biological and medical applications.He was active at the PTB in Berlin, the University of Ulm,(GE), the University of Chieti (IT) and the University of Jena (GE).He had cooperating with Siemens, General Electric and Atb. He joined all industrial efforts of BMDSys.

(For more information please see the CV)

Dr. Luigi Carlo De Micco

Luigi joined the company as consultant and investor in the beginning of 2014. He is an experienced entrepreneur and investment banker with a strong background in the growth development of IT and technology companies. He did and managed several IPO’s in European stock exchanges and at NASDAQ. Today Luigi is the CEO & president of the De Micco & Friends group which is represented with more than 200 lawyers, auditors and investment bankers in Europe.

(For more information please see the CV)

25www.demicco.ch

4.Market

26www.demicco.ch

4. Market overview4.1 Target groups

The largest sales potential is in hospitalsand large medical centers that offer heart diagnostics on the latest state of technology. APOLLO CXS offers acquisition, display and analysis of the magnetic signals of the human heart. Thus, several large diagnostic sectors in cardiology can be covered at the same time, e.g. risk stratification of future life-threatening arrhythmias and detection of acute and stress induced ischemia.

The alternative diagnostic methods do not provide the precision, comfort, efficiency or a combination of the mentioned criteria. Some of the alternatives are invasive and/or put high side effects to the patient .

Direct sales Sales via distributors Admission of health insurances

Med

ical 

facilities

Preven

tion

Sports

Special hospitals,universities

Sports centers

Sports centers

Sports organisations

Prevention

Modern practices

Cardiological hospitals

Large medical centers

Medical prevention

Cardiologists

27www.demicco.ch

4. Market overview4.2 Competitors

AtB, Pescara (Italy) (A)

AtB was founded in 1990 and had co-operations with the universities of Ulm and Jena for some years. It carried out orders of the universities and delivered a system named „Argos 200“ for magnetic heart measurement to the university of Jena. This company is not significantly active any more since 2006 and never established an industrial production of MFI systems. AtB does not offer an optical technology!

CardioMag Imaging (USA) (B)

Cardiomag sold in the past a 9-channel system for the measurement of the heart‘s magnetic field with which acute ischemia in the human heart can be detected. However, the recording bandwidth was so small and the noise so high that the system could not be used for risk stratification based on the QRS fragmentation. No optical technology available.

Elekta, Stockholm (Sweden) (C)

In a subsidiary of Elekta a system for electroencephalography (helmet shaped) is produced and sold. It is not possible to measure heart signals with this system and thus this product is no competition to our system. No optical technology available.

BMP Hamburg (Germany) (D)

In August 2010 the magnetocardiography (MCG) technology of KRISS was transferred to BiomagnetikPark GmbH. In January 2012 an MCG system of the company Biomagnetik Park GmbH was certified as a new medical device for the diagnose of coronary heart diseases according to the European Medical Directive 93/42/EEC. There is no compatible software for a risk stratification of sudden cardiac death. No optical technology available.

28www.demicco.ch

4. Market overview4.2 Competitors

All systems of competitors are based on superconductive sensors, i.e. they require helium cooling for operation.

Thus, those suppliers are no real competition for the optical system of BMDSys Optical GmbH.

The operation without helium is a unique selling proposition that is not offered by any competitor and saves approx. 900 K EURO of operation costs during 10 years (life cycle of a SQUID based MFI system).

Thus, the optical MFI system APOLLO CXS is unique in the whole world.

CompetitorA

CompetitorB

CompetitorC

CompetitorD

APOLLO CXS

Price ↑ ↓ ↔ ↑ ↓Performance ↑ ↓ ↙ ↔ ↑Regional marketshare ↓ ↓ ↓ ↓ ↓National marketshare ↓ ↓ ↓ ↓ ↓Regional acceptance ↔ ↔ ↔ ↔ ↑National acceptance ↔ ↔ ↔ ↔ ↑Product range ↔ ↓ ↔ ↗ ↓Marketing ↔ ↙ → ↔ ↔Innovation ↔ ↔ ↙ ↔ ↑Company size ↓ ↑ ↓ ↔ ↔On the marketsince 1990 2005 2000 ‐ 2005 2010 2008

Legend: ↑ very high; ↗ high; ↔ moderate; ↙ low; ↓ very low

29www.demicco.ch

4. Market overview4.3 Market potential

The market potential is enormous!

Considering the fact that no comparable product for heart diagnostics is available until now, BMDSys Optical GmbH has the potential for being a „global player“ in this segment. 

It can be supposed that BMDSys Optical GmbH first will have a monopoly position on the global market with its product. 

The developmental edge of approx. 5 years can hardly be caught up with even by larger companies that want to set up a competition.

600.0 bn

60.0 bn

75 %

2.0 bn

Market capacity global

Market volume

Scheduled market share until 2018

Market potential

30www.demicco.ch

5.Chances and risks

31www.demicco.ch

5. Chances and risksOptimum initial situation for investors

BMDSys Optical GmbH is in a classic „next‐ level‐position“.  The management and development team is well attuned, the main product is ready for market. 

The newly founded company is completely free from encumbrances  and can now start with an appropriate funding. 

Contrary to comparable technology companies where the main part of financial resources had to be invested in research and development BMDSys Optical GmbH provides a nearly finished and market‐ready product.

Chances

Best product on the market

Competitive edge can be secured in case of preferably soonest market entry

Potential for global player and market leader

Worldwide high demand  

Existing orders

Risks

Supply bottleneck at suppliers of applicable material  

Handling of the expected growth

Copying of the technology by competitors (very difficult)

32www.demicco.ch

6.Financial planning

33www.demicco.ch

6. Financial planning6.1 Sales figures

The sales figures of BMDSys Optical GmbH especially depend on the production capacities to be managed. In case of conservative planning, from  2nd. Year on 25 units, i.e. approximately twosystem per month, will be produced if the expected funding will be available. This means a turn over of already 14,6 mio. EURO.  Up from 3th. year the production will be increased to at least 32 units which means an average turn over of 18,6 mio. EURO.

Sales planning P1 P2 P3Price/system

China & US (Transfer of distribution contract) 500,000,00 € 2 7 16

Channel direct sales 650,000,00 € 0 2 5

Channel distribution 600,000,00 € 0 14 11

Mobile system option 380,000,00 € 2  2 0

Revenues from sales 1,760,000,00 € 14,590,000,00 € 18,170,000,00 €

Maintenance 20,000,00 € 0 80,000,00 € 500,000,00 €

Capital inflow from investors 3,000,000,00 €

Revenues in total 1,760,000,00 € 14,670,000,00 € 18,670,000,00 €

34www.demicco.ch

6. Financial planning6.2 Cost of materials 

The costs of material are calculated proportionally to the sold units. Based on the long delivery time of up to 3 months for single components, purchasing and financing has to be scheduled accordingly. 

Cost of materials P1 P2 P3Shelter 75,000,00 € 1,650,000,00 € 1,200,000,00 € 1,500,000,00 €Mu‐Metall 75,000,00 € 1,650,000,00 € 1,200,000,00 € 1,500,000,00 €Master console and workstation 12,000,00 € 264,000,00 € 192,000,00 € 240,000,00 €Elektronic hardware 40,000,00 € 880,000,00 € 640,000,00 € 800,000,00 €Laser 12,000,00 € 264,000,00 € 192,000,00 € 240,000,00 €Optical sensor 100,000,00 € 2,200,000,00 € 1,600,000,00 € 2,000,000,00 €Cosmetics und electrical infrastructur 12,000,00 € 264,000,00 € 192,000,00 € 240,000,00 €Other materials 12,000,00 € 264,000,00 € 192,000,00 € 240,000,00 €Installation 10,000,00 € 220,000,00 € 160,000,00 € 200,000,00 €

Cost of material / mashine 348,000,00 €Cost of material in total 7,656,000,00 € 5,568,000,00 € 6,960,000,00 €

35www.demicco.ch

6. Financial planning6.3 Cost of personnel

The costs for personnel increase with increasing production. For the two founders (CEO and CTO) an additional performance‐related bonus system should be developed. 

Cost of personnel P1 P2 P3Number of employees 18 18 18CEO 11,000,00 € 132,000,00 € 138,600,00 € 145,200,00 €CTO 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €Backoffice 5,000,00 € 55,000,00 € 63,000,00 € 66,000,00 €Software/Analysis 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €Software/ data base 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €QM 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €RealTime Software 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €Medical technics 5,900,00 € 53,100,00 € 74,340,00 € 77,880,00 €Elektronic 5,900,00 € 53,100,00 € 74,340,00 € 77,880,00 €Production eng. 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €Produkcion eng. 5,900,00 € 29,500,00 € 74,340,00 € 77,880,00 €Production assistance 4,200,00 € 37,800,00 € 52,920,00 € 55,440,00 €Production assistance 2 4,200,00 € 37,800,00 € 52,920,00 € 55,440,00 €Production assistance3 / Customer ralation 4,200,00 € 50,400,00 € 52,920,00 € 55,440,00 €Production assistance 4 4,200,00 € 8,400,00 € 52,920,00 € 55,440,00 €Production assistance 5 4,200,00 € 8,400,00 € 52,920,00 € 55,440,00 €Sales‐Rep 1 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €Sales‐Rep 2 5,900,00 € 64,900,00 € 74,340,00 € 77,880,00 €

Costs of personel 1,026,000,00 € 1,283,940,00 € 1,345,080,00 €

36www.demicco.ch

6. Financial planning6.4 Operational costs (without personnel)

Operational costs  P1 P2 P3Staff secondary costs 2% 20,520,00 € 25,678,80 € 26,901,60 €Fees (COC, associations etc.) 1,500,00 € 18,000,00 € 18,000,00 € 18,000,00 €Delivery costs 1,000,00 € 12,000,00 € 12,000,00 € 12,000,00 €Financial costs 1,500,00 € 18,000,00 € 18,000,00 € 18,000,00 €Recycling 2,000,00 € 24,000,00 € 24,000,00 € 24,000,00 €Lawyers 4,000,00 € 48,000,00 € 48,000,00 € 48,000,00 €Accountants 2,500,00 € 30,000,00 € 30,000,00 € 30,000,00 €Rent 15,000,00 € 120,000,00 € 180,000,00 € 216,000,00 €Energy 150,00 € 26,250,00 € 32,400,00 € 32,400,00 €Phone, communication 100,00 € 17,500,00 € 21,600,00 € 21,600,00 €Internet 500,00 € 6,000,00 € 6,000,00 € 6,000,00 €Cars 6,000,00 € 72,000,00 € 108,000,00 € 144,000,00 €Consultants 10,000,00 € 120,000,00 € 120,000,00 € 120,000,00 €CE + QM 1,500,00 € 18,000,00 € 18,000,00 € 18,000,00 €Cleaning 1,000,00 € 7,200,00 € 12,000,00 € 24,000,00 €Marketing 5,000,00 € 60,000,00 € 60,000,00 € 180,000,00 €Others 5,000,00 € 60,000,00 € 60,000,00 € 60,000,00 €Insurance 10,000,00 € 120,000,00 € 120,000,00 € 120,000,00 €

Office facilities 2,000,00 € 24,000,00 € 24,000,00 € 24,000,00 €

Exhibitions (4 /year, 2 national, 2 international) 100,000,00 € 0,00 € 400,000,00 € 800,000,00 €

Travel 4,000,00 € 36,000,00 € 96,000,00 € 124,800,00 €Reporting investor 5,000,00 € 0,00 € 20,000,00 € 20,000,00 €

Movement of company location 50,000,00 € 50,000,00 € 20,000,00 € 0,00 €

Installation costs 8,000,00 € 0,00 € 144,000,00 € 128,000,00 €

Maintenance Laser 700,00 € 8,400,00 € 8,400,00 € 8,400,00 €Software 10,000,00 € 10,000,00 € 10,000,00 € 10,000,00 €

Patents 20,000,00 € 30,000,00 € 60,000,00 €

Operational costs total 945,870,00 € 1,666,078,80 € 2,294,101,60 €

37www.demicco.ch

6. Financial planning6.5 Investments

For the first operational year only 900K EURO are necessary, with which the whole development and production process is covered. The previous company invested during it‘s operational time approx. 8 M. EURO. BMDSys Optical GmbH can proceed with it‘s activities completely unencumbered. 

Investments P1 P2 P3IRFA 90,000,00 € 90,000,00 € 0,00 € 0,00 €High permeable material 90,000,00 € 90,000,00 € 0,00 € 0,00 €Coil material 10,000,00 € 10,000,00 € 0,00 € 0,00 €New sensor head holder 25,000,00 € 25,000,00 € 0,00 € 0,00 €New sensor  head 60,000,00 € 60,000,00 € 0,00 € 0,00 €Non‐magnetic adjustable mattress 20,000,00 € 20,000,00 € 0,00 € 0,00 €Electronic hardware 100,000,00 € 100,000,00 € 0,00 € 0,00 €Office equipment 75,000,00 € 60,000,00 € 15,000,00 € 0,00 €Production equipment 150,000,00 € 75,000,00 € 75,000,00 € 0,00 €Field testing equipment 70,000,00 € 70,000,00 € 0,00 € 0,00 €Magnetic test equipment (2x) 40,000,00 € 80,000,00 € 0,00 € 0,00 €Basic optical equipment 60,000,00 € 60,000,00 € 0,00 € 0,00 €Forklifts (2x) 10,000,00 € 10,000,00 € 10,000,00 € 0,00 €Container transport system internally (2x) 100,000,00 € 100,000,00 € 100,000,00 € 0,00 €Power generation system for 110V / 60Hz (USA) 50,000,00 € 50,000,00 € 0,00 € 0,00 €

Investments total: 900,000,00 € 200,000,00 € 0

38www.demicco.ch

6. Financial planning6.6 Cash Flow Overview

When calculating conservatively, until the end of the year only a turnover of 1,7 M is achieved that results from existing orders. But depending on the time of the financing and delivering of components, within 9‐12 months sales profits can be achieved. The cash flow of the first year considers already the payment of an investment sum of 10 mio. EURO.

From the second year on (see business plan) the cash flow of the company is positive.  

Cash Flow P1 P2 P3Revenues 1,760,000,00 € 14,670,000,00 € 18,670,000,00 €Costs of materials 7,656,000,00 € 5,568,000,00 € 6,960,000,00 €Costs of personnel 1,026,000,00 € 1,283,940,00 € 1,345,080,00 €Operational costs without personnel 945,870,00 € 1,666,078,00 € 2,294,101,00 €

EBITDA:  ‐7,867,870,00 € 6,151,982,000,00 € 8,070,899,00 €

Cash Flow accumulated:  812,130,00 € 6,738,111,20 € 14,743,929,60 €Cash flow:  ‐87,870,00 € 5,638,111,20 € 14,543,929,60 €

39www.demicco.ch

6. Financial planning6.7 Capital demand

The actual capital demand of the company is 10 mio. EURO. 

The capital will be used in the following ways:

- Finishing the series-production readyness of the prototypeAPOLLO CXS

- Optimizing the production- Set up of national and international sales- National marketing aktivities- Continuing the health insurance license- Prefinancing the existing and future orders

40www.demicco.ch

7.Offer for investors

41www.demicco.ch

7. Offer for investors7.1 Participation

Interested investors can participate directly in the BMDSys Optical GmbH.

Considering the sales and profit and the enormous market- and development potential the company today is rated with minimum 32 mio. EURO.

The momentary proprietors offer investors a company share of up to 33 % for an exceptional price of 10 mio. EURO, which covers the momentary capital need.

With an committed institutional investor on board it’s possible to get a further finance by a German government institution (TBG) about 50% of the investors engagement on a loan basis.

42www.demicco.ch

7. Offer for investors7.2 Exit strategies

The management teams searches investors for medium and long term attendance. The actual business plan was set up for 3 years. From the 4th year on an industrial production should be established, that covers the demand. It can be assumed that the company than faces another developmental step.

Possible exit strategies from the momentary point of view:

- Rebuy of shares through the company owner- IPO, Reverse Merger- M&A transaction

43www.demicco.ch

Please contact us: 

Volker SchalleMail: vs@bmdsysoptical.comPhone: + 49 261 98279819Mobile: + 49 151 432 638 01

Dr. Luigi Carlo De Micco

eMail:  luigi@demicco.chPhone: + 34 871 944 532 Mobile:  + 34 637 216 267Web:  www.demicco.ch

Further questions?